PubRank

Eddie K Abdalla

Author PubWeight™ 171.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008 15.05
2 Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 5.78
3 The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg 2009 5.33
4 Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005 4.86
5 Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008 4.37
6 Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007 4.09
7 Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol 2007 3.45
8 Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008 3.36
9 Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009 3.22
10 Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004 2.62
11 Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007 2.62
12 Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008 2.52
13 Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 2009 2.44
14 Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005 2.43
15 Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009 2.35
16 High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011 2.28
17 Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009 2.27
18 Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007 2.26
19 Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002 2.21
20 Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003 2.20
21 Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007 2.12
22 Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006 2.06
23 Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010 2.04
24 Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003 2.03
25 Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002 2.03
26 Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004 2.01
27 Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004 1.99
28 Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005 1.84
29 The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res 2007 1.80
30 Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006 1.70
31 Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011 1.64
32 A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008 1.64
33 Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009 1.62
34 Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010 1.60
35 Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010 1.59
36 Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005 1.54
37 Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010 1.48
38 Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg 2005 1.44
39 Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005 1.44
40 Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011 1.43
41 Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005 1.43
42 Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010 1.42
43 Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008 1.41
44 Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010 1.38
45 The small remnant liver after major liver resection: how common and how relevant? Liver Transpl 2003 1.35
46 Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness--study in 26 patients. Radiology 2003 1.32
47 Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005 1.30
48 Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg 2007 1.25
49 Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2011 1.24
50 Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007 1.24
51 Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004 1.23
52 Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006 1.23
53 Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010 1.22
54 Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006 1.22
55 Comparison of two methods of future liver remnant volume measurement. J Gastrointest Surg 2007 1.21
56 Two-surgeon technique of parenchymal transection contributes to reduced transfusion rate in patients undergoing major hepatectomy: analysis of 1,557 consecutive liver resections. Surgery 2009 1.18
57 Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010 1.17
58 Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005 1.13
59 Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013 1.10
60 Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008 1.09
61 Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009 1.07
62 Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 2007 1.07
63 Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 2011 1.03
64 New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007 1.03
65 Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002 1.01
66 Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 2007 1.01
67 Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg 2011 1.00
68 Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol 2008 0.99
69 I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 2011 0.98
70 Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg 2012 0.98
71 Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008 0.97
72 Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 2006 0.97
73 High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 2007 0.96
74 Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford) 2012 0.96
75 Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012 0.94
76 Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 2012 0.93
77 Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 2011 0.93
78 Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004 0.92
79 Liver hanging maneuver for large or recurrent right upper quadrant tumors. J Am Coll Surg 2006 0.91
80 Prediction of Mortality After ALPPS Stage-1: An Analysis of 320 Patients From the International ALPPS Registry. Ann Surg 2015 0.90
81 A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009 0.89
82 Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 2011 0.88
83 Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 2011 0.88
84 Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am 2009 0.88
85 Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010 0.87
86 Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. HPB (Oxford) 2013 0.87
87 Operative considerations in resection of hilar cholangiocarcinoma. HPB (Oxford) 2005 0.86
88 Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 2013 0.83
89 Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009 0.83
90 Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2006 0.82
91 AHPBA/SSO/SSAT sponsored consensus conference on the multidisciplinary treatment of colorectal cancer metastases. HPB (Oxford) 2013 0.80
92 Improved survival after resection of colorectal liver metastases. J Clin Oncol 2006 0.79
93 Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Intervent Radiol 2008 0.79
94 Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009 0.78
95 Patient selection and outcome of hepatectomy for noncolorectal non-neuroendocrine liver metastases. Surg Oncol Clin N Am 2007 0.78
96 Technique and patient selection, not the needle, determine outcome of percutaneous intervention for hepatocellular carcinoma. Ann Surg Oncol 2004 0.77
97 Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol 2012 0.77
98 Colorectal metastases: resect or ablate? Ann Surg Oncol 2006 0.77
99 Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome. Surgery 2012 0.76
100 Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 2005 0.76
101 Liver transplantation for hepatocellular carcinoma: need for a new patient selection strategy. Ann Surg 2004 0.76
102 Eosinophilic cholangiopathy. Surgery 2002 0.76
103 Transdiaphragmatic radiofrequency ablation of liver tumors. J Am Coll Surg 2004 0.76
104 Staging of hepatocellular carcinoma. Hepatology 2005 0.75
105 Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol 2006 0.75
106 Unresectable hepatic colorectal metastases: need for new surgical strategies. Ann Surg Oncol 2006 0.75
107 The truth about radiofrequency ablation and laparoscopic liver resection. Ann Surg 2011 0.75
108 Focus on treatment of large hepatocellular carcinoma. Ann Surg Oncol 2004 0.75
109 Steatosis as a risk factor in liver surgery. Ann Surg 2007 0.75
110 Extrahepatic bile duct resection: standard treatment for advanced gallbladder cancer? J Surg Oncol 2006 0.75
111 Re: Right hepatic trisectionectomy for hepatobiliary disease: results and an appraisal of its current role. Ann Surg 2008 0.75
112 Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 2008 0.75
113 PREDICTORS OF INFLAMMATORY LOCAL RECURRENCE AFTER BREAST-CONSERVING THERAPY FOR BREAST CANCER: MATCHED CASE-CONTROL STUDY. J Med Liban 2016 0.75
114 Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006 0.75